bluebird bio Inc
(NAS:BLUE)
$
0.405
0.0272 (7.2%)
Market Cap: 78.75 Mil
Enterprise Value: 376.50 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 31/100 bluebird bio Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023 / 04:15PM GMT
Release Date Price:
$3.56
(-0.28%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have bluebird bio with CEO, Andrew Obenshain. Welcome, Andrew.
Andrew Obenshain
bluebird bio, Inc. - President, CEO & Director
Thank you, Jeff. Thanks for having me.
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
So for those who may not be familiar with bluebird bio, can you just provide a brief introduction?
Andrew Obenshain
bluebird bio, Inc. - President, CEO & Director
Sure. We are -- bluebird is a gene therapy company. We have a platform called
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot